Compound Interactions to Watch

Stacking compounds multiplies risk in ways a single-compound curve cannot show. The short answer: interactions happen on two levels. Pharmacokinetic, where one compound changes how fast another clears, and pharmacodynamic, where two compounds hit the same organ system and their effects stack. Our plotter flags known pairings as a live warning under the chart. You can run any combination through the interaction checker before you commit.

Compound by compound: the cardiovascular stack

The clearest example of pharmacodynamic stacking is combining a beta-2 agonist like Clenbuterol (Oral) with a PDE5 inhibitor like Tadalafil. Clenbuterol raises heart rate and cardiac output through beta-2 stimulation. Tadalafil, at the doses used recreationally in this context, lowers blood pressure through vasodilation. Combined, they compound tachycardia, blood-pressure swings, and arrhythmia risk.

The plotter shows a yellow interaction banner when both compounds are loaded. That banner is advisory, not a hard block. It exists to prompt research, not to grant clearance.

Trenbolone and thyroid function

Trenbolone (Trenbolone Acetate and the enanthate variant) is the most pharmacologically noisy compound in common use. Beyond the well-documented cardiovascular strain, trenbolone has a documented effect on thyroid hormone metabolism. It increases conversion of T4 to T3 in some users and accelerates thyroid hormone clearance, which can leave you feeling overheated, sweating at rest, and sleeping poorly.

This is a pharmacokinetic interaction at the enzyme level. If you add thyroid medication (T4 or T3) on top of trenbolone, the effect on circulating thyroid hormones becomes hard to predict. Trenbolone also raises prolactin in some men, which interacts with cabergoline use. Stacking two 19-nor steroids (trenbolone plus nandrolone) amplifies the prolactin and cardiovascular risks together.

If you are running trenbolone, draw TSH, free T3, and free T4 alongside your standard panel. Elevated T3 with suppressed TSH suggests the thyroid axis is being perturbed.

Testosterone and 5-alpha reductase

Testosterone is converted to dihydrotestosterone (DHT) by the 5-alpha reductase enzyme. DHT is the driver of androgenic side effects: hair loss in genetically prone men, prostate growth, and acne. A 5-alpha reductase inhibitor like finasteride or dutasteride reduces this conversion.

The interaction is pharmacokinetic at the enzyme level and pharmacodynamic downstream. Finasteride lowers DHT by roughly 70 percent and dutasteride by over 90 percent. This blunts the androgenic side effects of Testosterone Enanthate or Testosterone Cypionate. But DHT is not purely a villain. It supports libido, mood, and neurological function in men. Crushing it can cause post-finasteride syndrome symptoms in some users, including persistent low libido and brain fog, even after stopping.

Note that 5-alpha reductase inhibitors do not protect against DHT derived from compounds that are already DHT derivatives, like masteron or primobolan. They only affect testosterone’s conversion pathway.

Oral stacking and hepatic load

Most oral AAS (methandrostenolone, oxymetholone, fluoxymesterone, stanozolol, oxandrolone) are C17-alpha alkylated, a structural modification that lets them survive first-pass liver metabolism. This modification is also what makes them stressful on the liver. Stacking two or more orals compounds that hepatic load directly.

The harm-reduction card on each compound page flags hepatotoxicity severity. For reference, oxymetholone and fluoxymesterone carry the heaviest hepatic burden, while oxandrolone is comparatively mild but not benign. Adding an oral AAS plus an oral AI or SERM on top stacks three oral compounds through the same first-pass pathway. This is where liver enzyme panels (AST, ALT, GGT, bilirubin) become essential, drawn every 4 to 6 weeks while orals are running.

Compound and supplement interactions

Supplements interact too. Grapefruit juice inhibits CYP3A4, an enzyme that metabolizes many oral compounds, which can raise blood levels of an oral AAS well beyond the intended dose. Niacin and red yeast rice both affect the lipid panel and can compound the lipid damage AAS already cause. High-dose NSAIDs add renal stress on top of the blood-pressure load that AAS carry.

The cleanest harm-reduction approach is to avoid grapefruit and unnecessary new supplements while on cycle, and to treat anything that affects CYP enzymes, liver enzymes, or blood pressure as a potential interaction worth checking.

How to use the interaction checker

Add two or more compounds in the interaction checker tool. If a known interaction exists, a dismissible yellow banner appears with a short rationale and the affected system (cardiovascular, hepatic, endocrine). Use it as a prompt to research further, not as a green light. The checker covers documented pairings from the pharmacology literature. It does not predict novel or rare interactions.

Pair the checker with the main plotter to visualize how two compounds’ curves overlap in time. Two compounds with overlapping peaks hit a given organ harder at peak than either one alone.

FAQ

Does the interaction checker catch every dangerous combination? No. It surfaces documented pairings from the literature. Two compounds that are each mild can still combine into a problem the literature has not formally cataloged. Treat a clean checker result as “no known documented interaction,” not as “safe.”

Can I stack two orals if I keep the doses low? Dose matters, but the hepatic stress is not strictly linear. Running two C17-alpha alkylated orals at the same time is a clearly higher-risk pattern regardless of dose. Most harm-reduction guidance is to run one oral at a time and cap oral cycles at 4 to 6 weeks.

Will finasteride protect my hair on cycle? It helps with testosterone-derived DHT, which is the main driver of androgenic alopecia from testosterone esters. It does not protect against DHT-derivative compounds like masteron or primobolan, which are already reduced at the 5-alpha reductase step.

Does trenbolone really affect my thyroid? In many users it perturbs thyroid hormone levels, likely through increased T4-to-T3 conversion and faster clearance. If you run trenbolone, draw TSH, free T3, and free T4 and compare to baseline rather than assuming.

Should I take grapefruit juice to boost oral absorption? No. Grapefruit inhibits CYP3A4 unpredictably and can raise oral compound blood levels well above the intended range. It is a real pharmacokinetic interaction and a poor idea for harm reduction.

Sources

• Graham MR, et al. Cardiovascular risk and anabolic steroids. British Journal of Sports Medicine. PubMed PMID: 16799100. PubMed Central: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2657309/
• Friedel A, et al. Tadalafil pharmacokinetics and drug interactions. PubMed PMID: 16507814. PubMed Central: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1885023/
• Wilson JD. The role of 5-alpha-reduction in steroid hormone physiology. Journal of Clinical Endocrinology and Metabolism.
• Basaria S, et al. Clinical review: anabolic-androgenic steroid and cardiovascular risk. New England Journal of Medicine. PMID: 20592293.